What is Forest Laboratories Price-to-Operating-Cash-Flow?
As of today (2024-05-28), Forest Laboratories's share price is €72.50.
Forest Laboratories's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2014 was €1.26. Hence, Forest Laboratories's Price-to-Operating-Cash-Flow Ratio for today is 57.72.
The historical rank and industry rank for Forest Laboratories's Price-to-Operating-Cash-Flow or its related term are showing as below:
FRA:FQX'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.46 Med: 15.08 Max: 745.17
Current: 57.89
During the past 13 years, Forest Laboratories's highest Price-to-Operating-Cash-Flow Ratio was 745.17. The lowest was 5.46. And the median was 15.08.
Forest Laboratories's Cash Flow from Operations per share for the
three
months ended in Mar. 2014 was €0.36.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2014 was €1.26.
Forest Laboratories Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Forest Laboratories's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forest Laboratories Price-to-Operating-Cash-Flow Chart
|
Forest Laboratories Annual Data
|
|
Trend |
Mar05 |
Mar06 |
Mar07 |
Mar08 |
Mar09 |
Mar10 |
Mar11 |
Mar12 |
Mar13 |
Mar14 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
9.33 |
8.22 |
6.58 |
74.59 |
53.96 |
|
Forest Laboratories Quarterly Data
|
|
Jun09 |
Sep09 |
Dec09 |
Mar10 |
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
74.59 |
683.33 |
79.24 |
43.50 |
53.96 |
Competitive Comparison of Forest Laboratories's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forest Laboratories's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Forest Laboratories's Price-to-Operating-Cash-Flow falls into.
Forest Laboratories Price-to-Operating-Cash-Flow Calculation
Forest Laboratories's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 72.50 | / | 1.256 |
| = | 57.72 |
Forest Laboratories's Share Price of today is €72.50.
Forest Laboratories's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Forest Laboratories (FRA:FQX) Business Description
Traded in Other Exchanges
N/A
Address
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.
Forest Laboratories (FRA:FQX) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:FQX has been successfully added to your